Loading clinical trials...
Loading clinical trials...
This study will determine the safety and effectiveness of the drug Replagal for treating people with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called alpha-galactosida...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NCT06328608 · Fabry Disease
NCT06941025 · Fabry Disease, Pregnancy, and more
NCT06539624 · Fabry Disease
NCT06935578 · CADASIL, CADASIL (Diagnosis), and more
NCT04440254 · Fabry Disease
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions